Larimar Therapeutics Financials - Benzinga

Larimar Therapeutics Inc

LRMRNASDAQ

Trade with Public

Trade with Public

$3.15

0.0050.16%

最終更新: Sep 30, 2:58 PM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Larimar Therapeutics Financials

Larimar Therapeutics (LRMR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.39) by 23.08 percent. This is a 26.83 percent increase over losses of $(0.41) per share

Benzinga Newsdesk

PRO
Larimar Therapeutics Q1 EPS $(0.31) Beats $(0.54) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.54) by 42.59 percent. This is a 32.61 percent increase over losses of $(0.46) per share

Benzinga Newsdesk

Earnings Scheduled For March 19, 2026

Benzinga Insights

PRO
Larimar Therapeutics Q4 EPS $(0.73) Misses $(0.45) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.45) by 62.22 percent. This is a 62.22 percent decrease over losses of $(0.45) per share

Benzinga Newsdesk

PRO
Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.40) by 51.36 percent. This is a 154.17 percent decrease over losses of $(0.24) per

Benzinga Newsdesk

PRO
Larimar Therapeutics Q2 EPS $(0.41) Beats $(0.48) Estimate

Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.76 percent. This is a 20.59 percent decrease over losses of $(0.34) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved